Insider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells $5,648,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $28.24, for a total transaction of $5,648,000.00. Following the completion of the sale, the chief executive officer directly owned 1,647,546 shares of the company’s stock, valued at $46,526,699.04. The trade was a 10.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Eric Venker also recently made the following trade(s):

• On Friday, February 13th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $26.49, for a total transaction of $5,298,000.00.
• On Monday, January 12th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $21.92, for a total transaction of $4,384,000.00.
• On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.53, for a total value of $1,689,750.00.
• On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.45, for a total value of $4,490,000.00.

Roivant Sciences Price Performance

Shares of ROIV opened at $27.70 on Friday. The stock’s 50-day moving average is $25.92 and its two-hundred day moving average is $21.25. The stock has a market cap of $19.82 billion, a PE ratio of -23.68 and a beta of 1.17. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $30.33.

Wall Street Analyst Weigh In

Several analysts have issued reports on ROIV shares. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, March 4th. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Citigroup upped their target price on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. Guggenheim raised their price target on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, Leerink Partners lifted their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and an average target price of $29.50.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors have recently made changes to their positions in the business. Hsbc Holdings PLC acquired a new stake in shares of Roivant Sciences during the fourth quarter worth approximately $896,000. Pacer Advisors Inc. increased its stake in shares of Roivant Sciences by 24.0% in the fourth quarter. Pacer Advisors Inc. now owns 70,259 shares of the company’s stock worth $1,525,000 after buying an additional 13,609 shares during the last quarter. Dorsey Wright & Associates acquired a new stake in Roivant Sciences in the fourth quarter valued at $8,162,000. Invesco Ltd. boosted its stake in Roivant Sciences by 28.9% during the 4th quarter. Invesco Ltd. now owns 2,281,487 shares of the company’s stock valued at $49,508,000 after acquiring an additional 512,129 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new position in Roivant Sciences during the 4th quarter valued at $227,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.